Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30959 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Mona Hamdy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Hematology and BMT Unit, Faculty of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Carboxypeptidase B2, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Thrombin is a critical protease modulating thrombosis as well as inflammation, which are one of the main pathophysiological mechanisms in sickle vasculopathy, and its levels were reported to be high in sickle cell disease (SCD). The thrombin–thrombomodulin complex activates the TAFI inhibitor of fibrinolysis, which acts by reducing plasmin affinity for its substrate thus hindering fibrinolysis.
Objective
We aimed to determine the influence of the Thr325Ile single nucleotide polymorphism (SNP) on TAFI antigen levels and potential effects on the severity of SCD in a cohort of Egyptian patients.
Methods
Genotyping of Thr325lle polymorphism using Taq‐Man SNP genotyping assay and TAFI level measurement using an enzyme‐linked immunosorbent assay were performed for 80 SCD patients (45 homozygous HbSS, 16 S/β 0 and 19 Sβ + ) as well as 80 age‐ and gender‐matched healthy control subjects.
Results
Plasma TAFI levels were higher in SCD patients with Thr325Ile polymorphism, yet the difference was not statistically significant ( p = .204). SCD patients with polymorphic genotypes had a greater number of hospital admissions ( p = .03). Ten patients with acute chest syndrome had the homozygous polymorphic genotype (GG), and all patients with pulmonary hypertension had the polymorphic genotype (six were homozygous [GG] and five were heterozygous [GA]). Patients with SCD complicated with pulmonary hypertension showed significantly higher plasma TAFI levels ( p = .044).
Conclusion
The analysis of Thr325Ile polymorphisms combined with plasma TAFI levels suggests that the analyzed SNP could influence plasma TAFL levels and SCD disease severity and hospitalization rates, which could be predictors for complex disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Pediatric Hematology and BMT Unit, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.
ORCID-Profile: Mona Hamdy, Yasmeen M M Selim
Zitieren
APA
Hamdy, M., Shaheen, I. A., Khallaf, M., & Selim, Y. M. M. (2024). Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30959
Vancouver
Hamdy M, Shaheen IA, Khallaf M, Selim YMM. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30959
BibTeX
@article{Hamdy2024,
author = {Hamdy, Mona and Shaheen, Iman A and Khallaf, Mohamed and Selim, Yasmeen M M},
title = {Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30959}
}
EUVIMED